蒙古学龄儿童补充维生素D预防骨折:多中心、双盲、随机、安慰剂对照试验的次要结局分析
该多中心双盲随机安慰剂对照试验纳入蒙古乌兰巴托18所公立学校6-13岁学龄儿童8851名,随机分入每周口服14000 IU维生素D3组或安慰剂组,干预3年。骨折与安全性分析纳入8348名参与者,中位随访3.0年,维生素D组268名(6.4%)与安慰剂组253名(6.1%)报告至少一次骨折(校正RR 1.10,95%CI 0.93-1.29;p=0.27),不良事件发生率两组无差异。作者结论认为每周14000 IU维生素D补充3年安全,但未影响骨折风险。
要点
- 维生素D组268名(6.4%)与安慰剂组253名(6.1%)报告至少一次骨折,校正RR 1.10(95%CI 0.93-1.29;p=0.27)。
- 维生素D组与安慰剂组不良事件发生率无差异。
- 作者结论认为每周14000 IU维生素D补充3年安全,但未影响骨折风险。
核心结论
- 口服维生素D补充每周14000 IU、持续3年在蒙古学龄儿童中是安全的,但未影响骨折风险,尽管该人群基线维生素D缺乏患病率高。
研究设计与样本
- 多中心、双盲、随机、安慰剂对照试验,在蒙古乌兰巴托18所公立学校开展。
- 共邀请11475名儿童,招募并随机分配8851名至维生素D组(n=4418)或安慰剂组(n=4433),按就读学校分层置换区组随机化(1:1)。
- 维生素D组口服14 000国际单位(IU)维生素D3每周一次,安慰剂组对应处理,持续3年。
- 骨折与安全性分析纳入完成至少一次随访骨折问卷的8348名参与者(维生素D组4176名[94.5%],安慰剂组4172名[94.1%])。
主要发现
- 骨折与安全性分析人群中,4125名(49.4%)为女性,4223名(50.6%)为男性,7701名(92.2%)为喀尔喀血统。
- 中位年龄9.2岁(IQR 8.0-10.7),7975名(95.5%)参与者基线血清25-羟基维生素D浓度低于50 nmol/L。
- 中位随访3.0年(IQR 2.9-3.1)期间,维生素D组268名(6.4%)与安慰剂组253名(6.1%)报告至少一次骨折(校正RR 1.10,95%CI 0.93-1.29;p=0.27)。
- 维生素D组与安慰剂组不良事件发生率无差异。
关键数值与推荐
- 校正RR 1.10(95%CI 0.93-1.29;p=0.27),维生素D组骨折268名(6.4%)vs 安慰剂组253名(6.1%)。
临床怎么用
- 作者结论认为每周14000 IU维生素D补充3年安全,但未影响蒙古学龄儿童骨折风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vitamin D supplementation has been shown to increase total hip areal bone mineral density in healthy children and adolescents. We aimed to investigate whether supplementing schoolchildren living in Mongolia with weekly vitamin D3 for 3 years affected fracture risk. METHODS: We did a multicentre, double-blind, randomised, placebo-controlled trial across 18 public schools in Ulaanbaatar, Mongolia. Schoolchildren were eligible if they were aged 6-13 years at screening, had a negative QuantiFERON-TB Gold In-tube assay (QFT) result, were not hypersensitive to vitamin D or immunocompromised, did not use vitamin D supplements, did not have clinical signs of rickets, and had no intention of leaving Ulaanbaatar within 3 years. Participants were randomly assigned (1:1) to receive either vitamin D (oral dose of 14 000 international units [IU] vitamin D3, once per week) or placebo for 3 years using permuted block randomisation stratified by school of attendance. Participants, care providers, and all trial staff were masked to group assignment during the intervention. Prespecified secondary outcomes were incidence of fractures and adverse events, ascertained using questionnaires. The fracture and safety analyses included participants who completed at least one follow-up fracture questionnaire. We estimated adjusted risk ratios (RRs) and 95% CIs using generalised linear models with binomial distribution and a log link function with adjustment for school of attendance. The trial is registered with ClinicalTrials.gov, NCT02276755, and the intervention ended in May, 2019. FINDINGS: Between Sept 2, 2015, and March 20, 2017, 11 475 children were invited to participate in the study and 8851 were recruited and randomly assigned to receive either vitamin D (n=4418) or placebo (n=4433). 8348 participants were included in the fracture and safety analyses (4176 [94·5%] in the vitamin D group and 4172 [94·1%] in the placebo group). Of these, 4125 (49·4%) were female, 4223 (50·6%) were male, and 7701 (92·2%) were of Khalkh ancestry. Median age was 9·2 years (IQR 8·0-10·7) and 7975 (95·5%) participants had baseline serum 25-hydroxyvitamin D concentrations less than 50 nmol/L. During a median follow-up of 3·0 years (IQR 2·9-3·1), 268 (6·4%) participants in the vitamin D group and 253 (6·1%) in the placebo group reported one or more fractures (adjusted RR 1·10, 95% CI 0·93-1·29; p=0·27). Incidence of adverse events did not differ between study groups. INTERPRETATION: Oral vitamin D supplementation at a dose of 14 000 IU/week for 3 years was safe, but did not influence fracture risk in schoolchildren living in Mongolia who had a high baseline prevalence of vitamin D deficiency. FUNDING: US National Institutes of Health.
引用
- Ganmaa D, Khudyakov P, Buyanjargal U, et al. Vitamin D supplements for fracture prevention in schoolchildren in Mongolia: analysis of secondary outcomes from a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2023. PMID: 38048799. doi:10.1016/S2213-8587(23)00317-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。